|
Michael Grey was appointed to BioMarin's board of directors in December 2005. He currently serves as President and Chief Executive Officer of SGX Pharmaceuticals, Inc., a privately held biotechnology company. Prior to joining SGX Pharmaceuticals, Mr. Grey acted as President, Chief Executive Officer and board member of Trega Biosciences, Inc., a biotechnology company that was acquired by Lion bioscience AG in 2001. From November 1994 to August 1998, Mr. Grey was the President of BioChem Therapeutic, Inc., the pharmaceutical operating division of BioChem Pharma Inc., responsible for all company operations including research, development, sales and marketing, finance and human resources. Prior to this, in 1994, Mr. Grey served as President and Chief Operating Officer for Ansan, Inc. Earlier in his career, from 1974 to 1993, he served in various roles with Glaxo Inc. and Glaxo Holdings, plc, culminating in the position of Vice President, Corporate Development. Mr. Grey currently serves as a director of Achillion Pharmaceuticals, Inc. and IDM Pharma, Inc. (formerly known as Epimmune Inc.). He received a B.Sc. in Chemistry from the University of Nottingham, United Kingdom. | 